Literature DB >> 12540975

[Prevention of catheter-induced thromboses by low molecular weight heparins].

Ch Lersch1.   

Abstract

Infections and thromboses are the most frequent complications of central venous catheters (cvc). The use of a special material (i. e. polyurethane, silicone) and type (i. e. Hickman) small in diameter, the avoidance of any infection as well as the optimal position of the cvc tip in the lower part of the vena cava superior and a short period of catheterisation will be effective in decreasing the number of thromboses, whereas other thrombogenic factors (i. e. malignant disease), the patient's age, additional chemo- and/ or radiotherapy cannot practically be influenced. Coated cvc, oral anticoagulants, acetylsalicylic acid, and low dose urokinase, unfractionated and predominantly low molecular weight heparins (LMWH) are in use to avoid thromboses. Our outpatients with progressed gastrointestinal malignancies, port systems, and systemic chemotherapy consequently receive a prophylaxis with LMWH for at least 90 days according to the beneficial results published in three studies. Additional antitumoral effects of LMWH are presently evaluated and will favour consequent LMWH prophylaxis in patients with advanced malignancies and permanent catheters.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12540975

Source DB:  PubMed          Journal:  Hamostaseologie        ISSN: 0720-9355            Impact factor:   1.778


  2 in total

1.  [Indications, technique and complications of port implantation].

Authors:  L Haeder; J Jähne
Journal:  Chirurg       Date:  2013-07       Impact factor: 0.955

2.  THROMBOTECT - a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescents.

Authors:  Jeanette Greiner; Martin Schrappe; Alexander Claviez; Martin Zimmermann; Charlotte Niemeyer; Reinhard Kolb; Wolfgang Eberl; Frank Berthold; Eva Bergsträsser; Astrid Gnekow; Elisabeth Lassay; Peter Vorwerk; Melchior Lauten; Axel Sauerbrey; Johannes Rischewski; Andreas Beilken; Günter Henze; Wolfgang Korte; Anja Möricke
Journal:  Haematologica       Date:  2018-09-27       Impact factor: 9.941

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.